KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Equity (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Return on Equity for 8 consecutive years, with 0.06% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 5.0% year-over-year to 0.06%, compared with a TTM value of 0.06% through Dec 2025, up 5.0%, and an annual FY2025 reading of 0.07%, down 6.0% over the prior year.
  • Return on Equity was 0.06% for Q4 2025 at Esperion Therapeutics, down from 0.24% in the prior quarter.
  • Across five years, Return on Equity topped out at 1.13% in Q2 2021 and bottomed at 0.01% in Q4 2024.
  • Average Return on Equity over 5 years is 0.57%, with a median of 0.6% recorded in 2023.
  • Peak annual rise in Return on Equity hit 607bps in 2021, while the deepest fall reached -1675bps in 2021.
  • Year by year, Return on Equity stood at 0.98% in 2021, then fell by -22bps to 0.76% in 2022, then plummeted by -35bps to 0.5% in 2023, then crashed by -97bps to 0.01% in 2024, then surged by 406bps to 0.06% in 2025.
  • Business Quant data shows Return on Equity for ESPR at 0.06% in Q4 2025, 0.24% in Q3 2025, and 0.25% in Q2 2025.